Could TRexBio’s Treg bet crack the next big frontier in atopic dermatitis?
Atopic dermatitis has more drugs, but not enough durable control. TRexBio’s TRB-061 tests whether tissue Tregs can change that.
Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.
Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.